Stock 688180 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Equities

688180

CNE1000041Z1

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 13/06/2024 BST 		5-day change 1st Jan Change
28.69 CNY -5.62% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. -0.03% -31.41%
06-13 Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator MT
06-12 Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator
MT
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration
CI
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
MT
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
MT
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
GL
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
CI
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
MT
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
GL
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
CI
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes
CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection
MT
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
GL
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
CI
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA
MT
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection
CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.
CI
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
GL
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1877 Stock
  4. 688180 Stock
  5. News Shanghai Junshi Biosciences Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW